Short Summary
Kao Corporation appealed the rejection of its patent application (No. 5945/DELNP/2009) by the Joint Controller of Patents and Designs. The appeal challenged the ground that the applicant failed to file a rebuttal against non-patentability objections under Section 25(1)(f). The Court decided to issue notice to Respondent No. 2 before determining the matter.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Kao Corporation vs The Controller Of Patents & Anr. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Dunlop International Limited (and Dunlop Slazenger Group Ltd.)vsGlorious Investment Limited And Anr.
The Calcutta High Court set aside multiple appeals concerning the registration of the 'Dunlop' word mark. The core dispute revolved around the validity of assignments made by Dunlop India Ltd. during its liquidation period, which were used by Glorious Investment Limited to secure trademark rights in various classes. Given serious questions regarding fraud, natural justice violations, and the limited jurisdiction of the Registrar concerning assignment validity, the Court remanded all matters back for a fresh hearing after ensuring all parties are heard.
Glaxo Group LimitedvsGlenmark Pharmaceuticals Limited
The suit was filed by Glaxo Group Limited seeking rendition of accounts and recovery of money against Glenmark Pharmaceuticals Limited concerning Patent No. IN212714. The parties subsequently reached an amicable settlement, which the Court accepted and decreed the suit in terms of that agreement.
Dwd Pharmaceuticals LtdvsCelsius Healthcare Pvt Ltd
Dwd Pharmaceuticals Ltd sought an ex parte ad interim injunction against Celsius Healthcare Pvt Ltd for infringement of its ZEST family of trademarks. The court granted the injunction, restraining the defendant from using the impugned marks. The plaintiff had made significant investments in advertising its products under the ZEST trademarks and had generated considerable income. The defendant's use of the CELSIUSDIZEST mark was likely to cause irreparable harm to the plaintiff.
Novo Nordisk A/S & AnrvsDr. Reddy's Laboratories Limited
Novo Nordisk filed a commercial suit seeking an interim injunction against Dr. Reddy's Laboratories concerning their patented composition involving semaglutide. The court heard arguments, noted affidavits from both sides, and allowed procedural applications while directing the parties to proceed with pleadings.
Kudos Pharmaceuticals Limited & Ors.vsDr Reddys Laboratories Limited
The suit alleged infringement of several patents held by Kudos Pharmaceuticals Limited concerning Olaparib (LYNPARZA). The Plaintiffs contended that Dr. Reddy's Laboratories was manufacturing and exporting Olaparib API, violating their patent rights. The court decreed the suit, permanently restraining the Defendant from commercially launching the product before the patent expiry date, subject to Section 107A provisions.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.